title: Prediction of Trastuzumab Benefit in HER2-Positive Breast Cancers: Is It in the Intrinsic Subtype?
authors: Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
authors: Jisun
authors: J
authors: Kim
authors: Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
authors: Fresia
authors: F
authors: Pareja
authors: Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
authors: Britta
authors: B
authors: Weigelt
authors: Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
authors: Jorge S
authors: JS
authors: Reis-Filho
mesh_terms: D001943:Breast Neoplasms; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab